LifeMD, Inc. is classed by the SEC under Services-Offices & Clinics of Doctors of Medicine (industry code 8011), based in New York, NY. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $194 million and a profit of $11 million (its filed statements).
Usage businessServices-Offices & Clinics of Doctors of MedicineNew York, NYfilings since 20129 of 9 filed
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a usage business: prior from its industry code (SEC 8011, Services-Offices & Clinics of Doctors of Medicine); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.3 out of ten, 9 of 9 metrics filed: past 5.3 out of ten, present 7.1 out of ten, future 6.4 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 3.3 out of ten. 11 warning events since 2017; the latest 2025-11-12. 33rd percentile among 9 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 6.9 out of ten. +233.2% a year over 8 filed years; profitable in 1 of 8. 69th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 5.1 out of ten. Share count grew 13.4% a year. 28% of cash flow returned. Insiders: 1 sales, 0 purchases. 51st percentile among 6 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Financial health (present): 7.1 out of ten. ROE 62%: 62¢ of profit per shareholder dollar. Leverage 67%: owes 67¢ per asset dollar. 71st percentile among 9 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 6.2 out of ten. top 38% of 9 in its family; net margin 7.4%. 62nd percentile among 9 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 8.8 out of ten. top 12% of 5 in its family for leadership; chief executive since 2018. 88th percentile among 5 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 8.2 out of ten. top 18% of 9 in its family for room to expand. 82nd percentile among 9 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 5.2 out of ten. top 48% of 8 in its family for growth drivers. 52nd percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 6.9 out of ten. top 31% of 6 in its family for expectations against reality. 69th percentile among 6 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-10 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-05 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-05 (on EDGAR). Newest filing: Form SCHEDULE 13G/A, 2026-10-07. Filings on record since 2012. Read from EDGAR 2026-10-12.
Who runs it
Schreiber, Justin (Chairman and CEO); Kavthekar, Atul (Chief Financial Officer); Benathen, Marc David (Chief Financial Officer); Dray, Shayna Webb (Chief Operating Officer); Sripad, Umesh (Chief Technology Officer); Pisano, Christopher A (Chief Marketing Officer); Friedeman, Jessica (Chief Marketing Officer); Alvarez, Nicholas P (Chief Acquisition Officer); Galluppi, Stefan (Chief Innovation Officer); Stan, Maria E. (Chief Accounting Officer); and 7 more. 17 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.